ING Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

ING Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$985K	Buy	3,271 +1,982	+154%	+$598K	﹤0.01%	461
2026 Q1	$426K	Sell	1,289 -1,155	-47%	-$393K	﹤0.01%	473
2025 Q4	$972K	Buy	+2,444	New	+$1.08M	0.01%	478
2014 Q2	–	Sell	-10,949	Closed	-$735K	–	642
2014 Q1	$735K	Buy	+10,949	New	+$848K	﹤0.01%	590

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ING Group's ALNY Position: Q2 2026 in Review

ING Group increased its Alnylam Pharmaceuticals (ALNY) stake by 154% in Q2 2026, buying an estimated $598K and bringing the position to 3,271 shares worth $985K. The position accounts for ﹤0.01% of the portfolio, ranked #461.

ING Group first reported a position in ALNY in Q1 2014 and has held it in 4 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

ING Group held 3,271 shares of Alnylam Pharmaceuticals worth $985K as of Q2 2026.
ING Group bought 1,982 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $598K.
Alnylam Pharmaceuticals made up ﹤0.01% of ING Group's portfolio in Q2 2026, its #461 holding.
ING Group first reported a position in Alnylam Pharmaceuticals in Q1 2014 and has held it in 4 quarters since.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on ING Group's 13F filing for Q2 2026, filed 13 Aug 2026.